This Analyst Believes Seagen Is Evaluating Strategic Alternatives
Raymond James initiated coverage on Seagen Inc (NASDAQ: SGEN ) at Outperform with a $220 target price . Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck Company, Inc. (NYSE: MRK ) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable … Full story available on Benzinga.com
This Analyst Believes Seagen Is Evaluating Strategic Alternatives
Raymond James initiated coverage on Seagen Inc (NASDAQ: SGEN ) at Outperform with a $220 target price . Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck Company, Inc. (NYSE: MRK ) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable … Full story available on Benzinga.com